Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique

#54 Overactive bladder, urge incontinence and anticholinergic drugs

In patients with overactive bladder (OAB), or urge incontinence, how well do medications work and are any of them better?

Both anticholinergic drugs and placebo improve overactive bladder, although medications slightly more (about ½ a trip less to the bathroom/day). The drugs oxybutynin, tolterodinesolifenacin, and darifenacin are very similar in efficacy while adverse events (dry mouth and likely constipation) vary.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Overactive bladder (OAB) responds well to placebo1 but slightly more to anticholinergics.   
  • Systematic review,2 61 trials, 11,956 patients, comparing anticholinergic drugs like oxybutynin (Ditropan®) and tolterodine (Detrol®) to placebo, statistically significant difference: 
    • Patient reported cure or improve: 55.6% anticholinergic versus 41% placebo, Number Needed to Treat (NNT)=7. 
      • Anti-cholinergic reduced leaks 0.58/day better than placebo.  
      • Anti-cholinergic reduced micturitions 0.64/day better than placebo.      
    • Dry mouth was more common with anticholinergic (30.9% versus 9.8%). 
      • Withdrawal due to adverse events not different. 
  • Recent systematic review found similar.3 
  • Reviews comparing anticholinergic and other drugs: 
    • Comparing anticholinergics (i.e. oxybutynin versutolterodine):4 
      • Oxybutynin: more dry mouth (Number Needed to Harm (NNH)=6) and withdrawal (NNH=20). 
      • No difference in incontinence outcome. 
    • Extended versus immediate release formulations offer no advantage except perhaps less dry mouth.4   
    • Reviews by the Canadian Expert Drug Advisory Committee found: 
      • Darifenacin (Enablex®): No consistent difference to oxybutynin or tolterodine.5  
      • Solifenacin (Vesicare®): Less dry mouth than oxybutynin and some inconsistent results compared to tolterodine, showing possible worsening constipation but small improvements in incontinence symptoms.6 
  • Guidelines recommend confirming if a urinary tract infection (and treating as necessary), caffeine reduction and weight reduction, supervised bladder training, and anti-cholinergic bladder medications as needed.7   
  • All anticholinergic treatments increase the risk of constipation:  
    • Comparisons are limited but tolterodine appears to have the lowest risk.8  
updated may 25, 2015 by adrienne

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Christina Korownyk MD CCFP
  • G. Michael Allan MD CCFP

1. Lee S, Malhotra B, Creanga D, et al. BMC Medical Research Methodology. 2009; 9:55.

2. Nabi G, Cody JD, Ellis G, et al. Cochrane Database Syst Rev. 2006; (4):CD003781.

3. Reynolds WS, McPheeters M, Blume J, et al. Obstet Gynecol. 2015; 125(6):1423-32.

4. Madhuvrata P, Cody JD, Ellis G, et al. Cochrane Database Syst Rev. 2012; 1:CD005429.

5. Darifenacin, Notice of CEDAC Final Recommendation, April 16, 2009. Accessed 25 May 2015.

6. Solifenacin, Notice of CEDAC Final Recommendation, June 17, 2009. Accessed 25 May 2015.

7. Gormley EA, Lightner DJ, Burgio KL, et al. J Urol. 2012; 188(6 Suppl):2455-63.

8. Meek PD, Evang SD, Tadrous M, et al. Dig Dis Sci. 2011; 56:7-18.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 25/05/2015

By: Adrienne J Lindblad BSP ACPR PharmD


Evidence Updated: Systematic review added; Bottom Line: unchanged.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks